1-2 of 2
Belén Ojeda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

Javier Cortes, Serena Di Cosimo, Miguel A. Climent, Hernán Cortés-Funes, Ana Lluch, Pere Gascón, José I. Mayordomo, Miguel Gil, Manuel Benavides, Lluís Cirera, Belén Ojeda, César A. Rodríguez, José M. Trigo, Josep Vazquez, Pilar Regueiro, Juan F. Dorado, José Baselga, on behalf of the Spanish Breast Cancer Cooperative Group SOLTI
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 307–314.
https://doi.org/10.1158/1078-0432.CCR-08-1113
Published: 31 December 2008
View articletitled, Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study
Open the PDF for Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study in another window
Journal Articles

Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer

Ramon Colomer, Sagrario Montero, Ana Lluch, Belén Ojeda, Agustí Barnadas, Antonio Casado, Bartomeu Massutí, Hernán Cortés-Funes, Belén Lloveras
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2356–2362.
Published: 01 June 2000
View articletitled, Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer
Open the PDF for Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer in another window